LFCR LIFECORE BIOMEDICAL, INC. \DE\ Insider Trading

10% Owner English sells 1.39M shares (84.0% of holdings) for $9.1M across 3 transactions in May 2025.

English Aron R., a 10% owner of Lifecore Biomedical, executed three separate sales totaling 1,386,060 shares for $9,132,503.00 between May 23–28, reducing his stake from 1,650,240 shares to 264,180 shares (an 84.0% reduction). The sales occurred at prices ranging from $6.50 to $7.12, with a blended average of $6.59, near the current price of $6.90. The company reported a net loss of $-14.8M in its latest quarter against revenue of $35.2M, although it shows strong annual revenue growth of 24.2%. The substantial reduction in a 10% owner's position warrants attention given the company's unprofitable current state, though the timing and structured nature of the sales require deeper examination of whether this reflects discretionary portfolio decisions or reflects planned transactions.

CEO Josephs Paul purchases 17,000 shares of LFCR at $5.74; holds 559.7K shares post-transaction.

Josephs Paul, Chief Executive Officer, purchased 17,000 shares of LIFECORE BIOMEDICAL, INC. for $97,580.00, increasing his holdings from 542.7K shares to 559.7K shares (a 3.1% increase). The transaction occurred at $5.74 per share, below the current price of $5.80 and well below the 52-week high of $8.55, placing the purchase roughly 32.2% below the year's peak. The company reported $32.6M in quarterly revenue with net income of $-6.6M, and carries a P/E of 14.50 with a market cap of $214.7M, indicating ongoing losses offset by 24.2% year-over-year revenue growth. Over the preceding 90 days, the stock rallied 29.3%, though it declined 19.0% over the past 30 days, capturing the purchase near a recent local weakness following the recent advance.

Director Kiper buys 1,463,414 shares for $5,999,997.40 at $4.10; current price $5.09, down 40.5% from 52-week high.

Kiper Christopher S, a Director, executed 2 separate purchases totaling 1,463,414 shares for $5,999,997.40 at a blended average price of $4.10 per share. This acquisition is notable given the company's financial stress: LifeCore reported net income of -$16,230,000.00 in its latest quarter while generating $24,705,000.00 in revenue, and the stock is currently trading at $5.09, down 40.5% from its 52-week high of $8.55. The director's post-transaction holding of 319,286 shares contrasts with a pre-transaction position of -1,144,128 shares, indicating this purchase resolves a previous short or other negative position. The transaction represents a material capital commitment at a point of depressed valuation relative to recent historical range, though the company maintains positive annual revenue growth of 24.2% year-over-year.

Wynnfeld Partners adds 292,683 shares (12.6% increase) to 2.61M position in LFCR at $4.10; stock now -40.5% from 52-week high.

Wynnfeld Partners, a 10% owner of LIFECORE BIOMEDICAL, executed 2 separate purchases on 2024-10-03 totaling 292,683 shares for $1,200,000.30 at a blended average price of $4.10, expanding its position from 2,314,750 shares to 2,607,433 shares. The stock is trading 40.5% below its 52-week high of $8.55 and has gained 6.7% over the past 30 days. LIFECORE is unprofitable (net income of $-16,230,000.00 in the latest quarter) despite 24.2% annual revenue growth, trading at a P/E of 24.24 on a market cap of $157,272,117.95. Wynnfeld's cross-ticker track record shows 20 prior open-market buys with an average 30-day return of +8.8% and a 90-day win rate of 47.37%, providing a baseline of performance but not ticker-specific evidence. The magnitude of this purchase—a 12.6% increase in holdings at a price substantially below the 52-week high—occurs as the stock has recently recovered from broader weakness, though LIFECORE's unprofitability and elevated valuation relative to its losses warrant scrutiny of the thesis underlying the accumulation.